[PERSON]
Ania M. Jastreboff
Featured in 2 tracked stories · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
112 clusters · 548 sources · last updated
Latest: Novo Nordisk faces intense competition in obesity drug market
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,
Clinical trials for pediatric and adolescent obesity
2 clusters · 6 sources · last updated
Latest: Ecknoglutide shows significant weight loss in adolescent obesity trials
Clinical trials for obesity treatments targeting children and adolescents have reported positive results for new medications. In September 2026, Novo Nordisk announced that its phase 3 STEP Young trial for semaglutide m